TY - JOUR
T1 - Cardiovascular disease burden in patients with urological cancers
T2 - The new discipline of uro-cardio-oncology
AU - Zheng, Yi
AU - Liu, Ying
AU - Chen, Ziliang
AU - Zhang, Yunpeng
AU - Qi, Zuo
AU - Wu, Ning
AU - Zhao, Zhiqiang
AU - Tse, Gary
AU - Wang, Yong
AU - Hu, Hailong
AU - Niu, Yuanjie
AU - Liu, Tong
N1 - Publisher Copyright:
© 2024 The Authors. Cancer Innovation published by John Wiley & Sons Ltd on behalf of Tsinghua University Press.
PY - 2024/4
Y1 - 2024/4
N2 - Cancer remains a major cause of mortality worldwide, and urological cancers are the most common cancers among men. Several therapeutic agents have been used to treat urological cancer, leading to improved survival for patients. However, this has been accompanied by an increase in the frequency of survivors with cardiovascular complications caused by anticancer medications. Here, we propose the novel discipline of uro-cardio-oncology, an evolving subspecialty focused on the complex interactions between cardiovascular disease and urological cancer. In this comprehensive review, we discuss the various cardiovascular toxicities induced by different classes of antineoplastic agents used to treat urological cancers, including androgen deprivation therapy, vascular endothelial growth factor receptor tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics. In addition, we discuss possible mechanisms underlying the cardiovascular toxicity associated with anticancer therapy and outline strategies for the surveillance, diagnosis, and effective management of cardiovascular complications. Finally, we provide an analysis of future perspectives in this emerging specialty, identifying areas in need of further research.
AB - Cancer remains a major cause of mortality worldwide, and urological cancers are the most common cancers among men. Several therapeutic agents have been used to treat urological cancer, leading to improved survival for patients. However, this has been accompanied by an increase in the frequency of survivors with cardiovascular complications caused by anticancer medications. Here, we propose the novel discipline of uro-cardio-oncology, an evolving subspecialty focused on the complex interactions between cardiovascular disease and urological cancer. In this comprehensive review, we discuss the various cardiovascular toxicities induced by different classes of antineoplastic agents used to treat urological cancers, including androgen deprivation therapy, vascular endothelial growth factor receptor tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics. In addition, we discuss possible mechanisms underlying the cardiovascular toxicity associated with anticancer therapy and outline strategies for the surveillance, diagnosis, and effective management of cardiovascular complications. Finally, we provide an analysis of future perspectives in this emerging specialty, identifying areas in need of further research.
KW - anticancer therapy
KW - cardiovascular toxicity
KW - mechanism
KW - multidisciplinary management
KW - urological cancer
UR - http://www.scopus.com/inward/record.url?scp=85195043668&partnerID=8YFLogxK
U2 - 10.1002/cai2.108
DO - 10.1002/cai2.108
M3 - Review article
AN - SCOPUS:85195043668
SN - 2770-9191
VL - 3
JO - Cancer Innovation
JF - Cancer Innovation
IS - 2
M1 - e108
ER -